Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proved breast cancer~* Relapse/recurrent brain metastasis progression after brain radiotherapy~* Presence of brain measurable disease which is defined as at least one brain lesion that can be measured in at least 1 dimension as ³ 20 mm with magnetic resonance image (MRI)~* Prior chemotherapy or hormone therapy for metastatic breast cancer is allowed~* Performance status of ECOG 0, 1, 2~* With normal left ventricular ejection fraction and normal ventricular contractility~* Age 21 years or older~* Life expectancy equal or longer than 3 months~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Prior anthracycline-containing chemotherapy with cumulative dose exceed 400mg/m2 doxorubicin or 750 mg/m2 Epirubicin~* Surgery , radiotherapy, hormonal therapy or chemotherapy within 4 weeks prior to entering the study~* Prior liposomal doxorubicin treatment~* Concurrent chemotherapy, radiotherapy, hormonal therapy, or other investigational drug except non-disease related conditions (e.g. insulin for diabetes) during study period~* Other malignancy with exception of curative treated non-melanoma skin cancer or cervical carcinoma in situ within 5 years prior to entering the study~* Brain metastases defined as meninges metastases~* Presence of serious concomitant illness which might be aggravated by study medication:~  * Uncontrolled infection (active serious infections that are not controlled by antibiotics)~ * Active cardiac disease e.g. decompensate myocardial infarction within the 6-month period preceding entry into the study.~ * History of ventricular arrhythmia or congestive heart failure.~* Presence of abnormal left ventricular ejection fraction~* Hematopoietic function as defined below:~  * Hemoglobin\<10g/dl~ * ANC\< 1,500/uL~ * Platelets\<100,000/uL~* Organ function as defined below:~  * Total bilirubin \>1.5 × ULN~ * ALT / AST\>3 × ULN (\>5.0 x ULN if hepatic metastasis)~ * Creatinine \>1.5 × ULN~* Mental status is not fit for clinical trial~* Pregnant or breast feeding women, or women of child-bearing potential unless using a reliable and appropriate contraceptive method

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).